Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 24 November 2025 - 26 November 2025

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer (PFE) Stock Today, November 26, 2025: Options Surge, Obesity Bet and Cancer Win Shape the Outlook

Pfizer Inc. (NYSE: PFE) heads into Wednesday, November 26, 2025 with its share price sitting just under the top of its recent trading range and a narrative that looks very different from the COVID‑era boom and bust. After climbing almost 2% on Tuesday to about $25.72 per share, Pfizer now offers a dividend yield near 6.7%, trades in a 52‑week…
26 November 2025
···
Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck (MRK) Stock Soars on FDA Keytruda Approval and Wells Fargo Upgrade – 25 November 2025

Merck & Co., Inc. (NYSE: MRK) is back in the market’s spotlight this Tuesday, with the pharmaceutical giant’s shares extending a powerful rally fuelled by fresh regulatory wins and a major Wall Street upgrade. As of early-afternoon trading on 25 November 2025, Merck stock is changing hands around $104–$105, up roughly 4% on the day and trading just below its…
25 November 2025
··
NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Key takeaways NVO stock today: price and trading snapshot (Nov. 25, 2025) As of late‑afternoon trading on Tuesday, November 25, 2025, Novo Nordisk A/S American Depositary Receipts (ADR), ticker NVO on the NYSE, were changing hands at about $47.08, up $2.11 on the session — a gain of roughly 4.7% versus Monday’s close. Intraday, NVO has: Despite today’s rally, NVO…
25 November 2025
·
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company (NYSE: LLY) continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum and ongoing institutional and retail interest. Eli Lilly stock price today (25 November 2025) Eli Lilly shares closed around $1,092.4…
25 November 2025
····
German Stock Market Today: DAX Rebounds as Bayer Surges on Stroke‑Drug Breakthrough – 24 November 2025

German Stock Market Today: DAX Rebounds as Bayer Surges on Stroke‑Drug Breakthrough – 24 November 2025

Germany’s stock market kicked off the new week with a relief rally on Monday, 24 November 2025 (24.11.2025). The blue‑chip DAX 40 climbed around 0.7% to close just above 23,200 points, helped by a double‑digit jump in Bayer and renewed optimism about global interest‑rate cuts, even as the latest Ifo business climate index once again highlighted the fragility of Europe’s…
25 November 2025
··
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys. SRPT stock today at a glance As of Monday’s close (November 24, 2025), here’s…
25 November 2025
····
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying…
25 November 2025
···
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within a few percent of its 52‑week high. StockAnalysis The move comes as Wells Fargo upgraded Merck to “Overweight” from “Equal…
24 November 2025
····
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move that stands out Bristol Myers Squibb shares climbed sharply on Monday, with BMY changing hands around $48.24, up roughly $1.99…
24 November 2025
····
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Published November 24, 2025 Eli Lilly has done something no other health‑care company has ever achieved: it has joined the $1 trillion market‑capitalization club, a group previously dominated almost entirely by technology giants like Apple, Microsoft and Nvidia. After briefly crossing the 13‑figure threshold on Friday, Lilly’s stock was still trading around $1,058 per share on Monday, valuing the Indianapolis‑based…
24 November 2025
···
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO fallen? Novo Nordisk’s Alzheimer’s setback is hitting the share price hard on Monday, 24 November 2025: Despite the sell‑off, Novo…
24 November 2025
···
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Snapshot: Where RXRX Stands Going Into the New Week Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at roughly 33 million shares, and the stock now trades near the bottom of its 52‑week range of $3.79–$12.36. StockInvest The…
24 November 2025
····
1 … 33 34 35 36 37 … 46

Stock Market Today

  • Halliburton (HAL) Shows Potential Undervaluation Despite Multi-Year Gains
    January 22, 2026, 12:47 PM EST. Halliburton's (HAL) stock closed at $33.36, reflecting 20.6% returns over the past year and a 111% gain over five years, though it declined 10.8% in three years. The energy services sector remains under scrutiny amid fluctuating investor interest. A Discounted Cash Flow (DCF) analysis, which estimates intrinsic value by projecting future cash flows discounted to present value, places Halliburton's intrinsic worth at $75.44 per share. This suggests the stock trades at a 55.8% discount to its modeled value, indicating potential undervaluation. While the company's P/E ratio helps assess earnings relative to share price, Halliburton scores 3 out of 6 on valuation checks, pointing to mixed signals in its price and growth outlook.
Go toTop